Rintatolimod-Durvalumab Combination Shows Promise in Metastatic Pancreatic Cancer Phase 2 Trial
核心洞察
Preliminary data from the DURIPANC Phase 2 trial shows 21% of metastatic pancreatic cancer (搜索) patients achieved progression-free survival exceeding 6 months with rintatolimod plus durvalumab combination therapy.
The combination demonstrated a favorable safety profile with no significant toxicity in 14 enrolled patients who had previously received FOLFIRINOX chemotherapy.
Early survival data indicates 64% of patients achieved overall survival greater than 6 months, outperforming historical benchmarks in this aggressive disease setting.
Preliminary mid-year data from the ongoing DURIPANC Phase 2 clinical trial has demonstrated encouraging early outcomes for the combination of rintatolimod (Ampligen) and durvalumab (Imfinzi) in treating metastatic pancreatic cancer (搜索) patients following FOLFIRINOX chemotherapy. The investigator-initiated study, conducted through a collaboration between AIM ImmunoTech Inc, AstraZeneca, and Erasmus Medical Center in the Netherlands, suggests potential advancement in a historically challenging therapeutic area.
Trial Design and Patient Population
The DURIPANC study (NCT05927142) is an exploratory, open-label, single-center trial designed to enroll up to 25 patients in its Phase 2 portion. As of the mid-year report, 14 patients have been enrolled. The trial targets metastatic pancreatic ductal adenocarcinoma (搜索) patients who have achieved stable disease after FOLFIRINOX chemotherapy, a standard but palliative treatment regimen.
The combination therapy pairs rintatolimod, a TLR3 (搜索) agonist that activates dendritic cells and enhances T-cell responses, with durvalumab, an anti-PD-L1 (搜索) checkpoint inhibitor. This dual mechanism approach aims to overcome the immunosuppressive tumor microenvironment that renders pancreatic cancer resistant to single-agent immunotherapies.
Safety and Efficacy Results
The combination therapy has demonstrated no significant toxicity, indicating an encouraging safety profile for patients in a post-chemotherapy setting. This finding is particularly crucial for a patient population often debilitated by prior intensive treatments.
Efficacy data shows that approximately 21% of patients (3 out of 14) have achieved progression-free survival exceeding 6 months, with an additional 21% yet to experience disease progression. This early indication of prolonged disease control is noteworthy in metastatic pancreatic cancer (搜索), where rapid progression is common.
Overall survival data reveals that 64% of patients have achieved survival greater than 6 months. This early survival data is considered better than expected in this aggressive disease setting, outperforming historical benchmarks for this patient population.
Clinical Context and Significance
Pancreatic cancer remains one of the most lethal malignancies, with a five-year survival rate of less than 10%. The disease is notoriously difficult to treat, with limited responsiveness to immunotherapy, particularly in unselected patient populations. Following initial FOLFIRINOX chemotherapy, maintenance or second-line immunotherapies have historically offered only limited survival benefits in comparative trials.
"Our preliminary data suggests that the combination of [rintatolimod] and durvalumab is well tolerated in post-FOLFIRINOX pancreatic cancer patients, with encouraging preliminary survival data, especially given the historical difficulty of improving outcomes in this setting," said Casper van Eijck, MD, PhD, of Erasmus Medical Center.
Development Background
AIM ImmunoTech's focus on pancreatic cancer treatment with rintatolimod spans several years. Since 2017, over 50 patients with pancreatic cancer have received rintatolimod as an immuno-oncology monotherapy under a Dutch government-approved Compassionate Use/Early Access Program at Erasmus Medical Center, with van Eijck as the lead investigator. This program generated detailed analyses suggesting rintatolimod's potential effectiveness as a monotherapy, laying the groundwork for the DURIPANC study.
The DURIPANC trial was initiated in January 2023 through clinical agreements between AIM ImmunoTech, AstraZeneca, and Erasmus Medical Center. The study is partially funded by AstraZeneca and Erasmus MC, with enrollment expected to complete by Q2/Q3 2026.
Intellectual Property and Market Position
AIM ImmunoTech has secured intellectual property protection specific to pancreatic cancer, including a recently issued US patent for rintatolimod as an oncology treatment in combination with an anti-PD-L1 (搜索) agent, extending protection to August 9, 2039. The company also holds orphan drug designations for rintatolimod in pancreatic cancer in both the US and the European Union, which could grant years of market exclusivity post commercial approval.
The global pancreatic cancer immunotherapy market is projected to grow at a 13.6% CAGR, reaching $13.01 billion by 2037, driven by rising incidence rates and the high cost of care for late-stage patients. The DURIPANC trial targets a subset of this market where no FDA-approved immunotherapy currently exists for patients who have progressed on FOLFIRINOX.